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In the last decades, a lot of attention has been paid to the compounds present in medicinal Cannabis sativa L., such as Δ9-
tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), and their effects on inflammation and cancer-related pain. The National
Cancer Institute (NCI) currently recognizes medicinal C. sativa as an effective treatment for providing relief in a number of
symptoms associatedwith cancer, including pain, loss of appetite, nausea and vomiting, and anxiety. Several studies have described
CBD as amultitarget molecule, acting as an adaptogen, and as a modulator, in different ways, depending on the type and location of
disequilibrium both in the brain and in the body, mainly interactingwith specific receptor proteins CB
1
and CB
2
. CBD is present in
both medicinal and fibre-type C. sativa plants, but, unlike Δ9-THC, it is completely nonpsychoactive. Fibre-type C. sativa (hemp)
differs from medicinal C. sativa, since it contains only few levels of Δ9-THC and high levels of CBD and related nonpsychoactive
compounds. In recent years, a number of preclinical researches have been focused on the role of CBD as an anticancer molecule,
suggestingCBD(andCBD-likemolecules present in the hempextract) as a possible candidate for future clinical trials. CBDhasbeen
found to possess antioxidant activity in many studies, thus suggesting a possible role in the prevention of both neurodegenerative
and cardiovascular diseases. In animal models, CBD has been shown to inhibit the progression of several cancer types. Moreover,
it has been found that coadministration of CBD and Δ9-THC, followed by radiation therapy, causes an increase of autophagy
and apoptosis in cancer cells. In addition, CBD is able to inhibit cell proliferation and to increase apoptosis in different types of
cancer models. These activities seem to involve also alternative pathways, such as the interactions with TRPV and GRP55 receptor
complexes. Moreover, the finding that the acidic precursor of CBD (cannabidiolic acid, CBDA) is able to inhibit the migration of
breast cancer cells and to downregulate the proto-oncogene c-fos and the cyclooxygenase-2 (COX-2) highlights the possibility that
CBDA might act on a common pathway of inflammation and cancer mechanisms, which might be responsible for its anticancer
activity. In the light of all these findings, in this reviewwe explore the effects and themolecularmechanisms ofCBDon inflammation
and cancer processes, highlighting also the role of minor cannabinoids and noncannabinoids constituents of Δ9-THC deprived
hemp.
1. The Chemistry of Cannabis sativa L.
Cannabis sativa L. is a dioicous plant of the Cannabaceae
family and it is widely distributed all over the world [1]. It
has been used as a psychoactive drug, as a folk medicine
ingredient, and as a source of textile fibre since ancient times
[2]. The taxonomic classification of this plant has always
been difficult, due to its genetic variability [1, 3]. Firstly, the
genus Cannabis has been divided into three main species
[1, 3, 4]: a fibre-type one, named C. sativa L., a drug-type one,
characterised by high levels of the psychoactive compound
Δ9-tetrahydrocannabinol (Δ9-THC), named C. indica Lam.,
and another one with intermediate properties, named C.
ruderalis Janisch. Due the easy crossbreeding of these species
to generate hybrids, a monotypic classification has been
preferred, in which one species (C. sativa) is recognised
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and it is divided into different chemotypes [1, 3, 4]. On
the basis of their cannabinoid profiles, five chemotypes have
been recognised: chemotype I comprises drug type plants
with a predominance of Δ9-THC-type cannabinoids; chemo-
types III and IV are fibre-type plants containing high levels
of nonpsychoactive cannabinoids and very low amounts
of psychoactive ones; chemotype II comprises plants with
intermediate characteristics between drug-type and fibre-
type plants; chemotype V is composed of fibre-type plants
which contains almost no cannabinoids [5].
For both medicinal and forensic purposes, the most
important classification of Cannabis types is that into the
drug-type and the fibre-type: the drug-type Cannabis, which
is rich in psychoactive Δ9-THC, is used for medicinal or
recreational purposes; the fibre-type Cannabis, rich of can-
nabidiol (CBD) or related compounds and almost devoid of
Δ9-THC, is used for textile or food purposes [3]. Indeed,
the well-known pharmacological activity of psychoactive
cannabinoid Δ9-THC makes drug-type Cannabis one of the
most investigated medicinal plants [3]. Fibre-type Cannabis
(also known as hemp or industrial hemp) is at the moment
underemployed for pharmacological purposes, while drug-
typeC. sativa is used in several diseases as a palliative therapy
or in coadministration with primary therapy [1]. However,
there has also been a growing interest in fibre-type C. sativa
varieties in recent years [1], and those approved for commer-
cial use by the European Community are 69 [5]. Many Euro-
pean countries have recognized the commercial value of
hemp and a legal limit of 0.2-0.3% Δ9-THC is usually applied
[1].
C. sativa is characterized by a complex chemical com-
position, including terpenes, carbohydrates, fatty acids and
their esters, amides, amines, phytosterols, phenolic com-
pounds, and the specific compounds of this plant, namely, the
cannabinoids [2]. Cannabinoids are meroterpenoids (specifi-
cally C
21
or C
22
terpenophenolic compounds), obtained from
the alkylation of an alkyl resorcinol with a monoterpene
unit [3].They are mainly synthesized in glandular trichomes,
which are more abundant in female inflorescences [2]. More
than 100 cannabinoids have been isolated, characterised,
and divided into 11 chemical classes [4, 6]. Usually, the
most abundant cannabinoids present in drug-type plants
are Δ9-tetrahydrocannabinolic acid (Δ9-THCA) and Δ9-
THC, while fibre-type plants are known to contain mainly
cannabinoic acids, such as cannabidiolic acid (CBDA) and
cannabigerolic acid (CBGA), followed by their decarboxy-
lated forms, namely, cannabidiol (CBD) and cannabigerol
(CBG) (Figure 1) [7, 8]. Other minor cannabinoids include
cannabichromenic acid (CBCA), cannabichromene (CBC),
cannabinolic acid (CBNA), and cannabinol (CBN), with the
last two being the oxidative degradation products of Δ9-
THCA and Δ9-THC, respectively, present in aged Cannabis
(Figure 1) [1, 3, 4, 7–10]. Δ9-THC can also be transformed by
isomerization to Δ8-THC (Figure 1), which is an artefact. It
should be pointed out that cannabinoids are biosynthesized
in the acid form in plant tissues; then, they can generate their
decarboxylated counterparts under the action of heat and
light, by means of a spontaneous decarboxylation [1, 3, 4, 7–
10].
Many of the psychoactive effects of Δ9-THC are mediated
by CB
1
receptors, while nonpsychoactive cannabinoids, such
as CBD, have low affinity for both CB
1
and CB
2
receptors
[3]. The interaction with CB
1
receptors is responsible for the
analgesic effect of Δ9-THC, due to their role in the transmis-
sion of the nociceptive information in various tissues [3]. CB
2
receptors are highly expressed in some cells of the immune
system and they are believed to have a role in the immune cell
function, thus explaining the immunomodulatory properties
of Δ9-THC. CB
2
receptors are also considered to be involved
in neuroinflammation, atherosclerosis, and bone remodelling
[3].
In the ambit of nonpsychoactive compounds, CBD repre-
sents the most valuable one from the pharmaceutical point of
view, since it has been found to possess a high antioxidant and
anti-inflammatory activity, together with antibiotic, neuro-
protective, anxiolytic, and anticonvulsant properties [1, 3, 11–
14]. CBDA has antimicrobial and antinausea properties [1,
11, 13], while CBG has anti-inflammatory, antimicrobial, and
analgesic activities [1, 11, 13, 15].Thanks to its lack of psychoac-
tivity, CBD is one of the most interesting compounds, with
many reported pharmacological effects in various models
of pathologies, from inflammatory and neurodegenerative
diseases, to epilepsy, autoimmune disorders like multiple
sclerosis, arthritis, schizophrenia, and cancer [16]. In the
presence of Δ9-THC, CBD is able to antagonize CB
1
at low
concentration; this supports its regulatory properties on Δ9-
THC adverse effects like tachycardia, anxiety, sedation, and
hunger in animals and humans [16]. CBDhas also been found
to be a negative allosteric modulator of the CB
1
receptors
and an inverse agonist of CB
2
receptors, the second activity
partly explaining its anti-inflammatory activity [16]. Different
targets have been described in the literature for nonpsy-
choactive cannabinoids, including the transient potential
vanilloid receptor type-1 (TPVR-1) channels, the peroxisome
proliferator-activated receptor 𝛾 (PPAR𝛾) GPR55, the 5-
hydroxytryptamine receptor subtype 1A (5-HT1A), glycine
𝛼1 and 𝛼1𝛽 receptors, the adenosine membrane transporter
phospholipase A2, lipoxygenase (LO) and cyclooxygenase-2
(COX-2) enzymes, and Ca2+ homeostasis [11, 16].
Concerning other phenolics present in C. sativa, sev-
eral flavonoids have been identified, belonging mainly to
flavones and flavonols, together with cannflavins A and B,
which are C. sativa typical methylated isoprenoid flavones
[17]. Cannabis flavonoids exert several biological effects,
including properties possessed also by cannabinoids and
terpenes [2]. Anti-inflammatory, neuroprotective, and anti-
cancer activities have been described for these compounds
[2]. In particular, cannflavin A and B are known to possess
an anti-inflammatory action [2]. Microsomal prostaglandin
E
2
synthase (mPGES-1) and 5-LO have been identified as
the molecular targets of cannflavins A and B [18]. An
antimicrobial and antileishmanial activity has also been
demonstrated for cannflavin B [17]. Cannflavin A has shown
a good antileishmanial activity and a moderate antioxidant
action [17]. In the ambit of Cannabis phenolics, canniprene,
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Figure 1: Chemical structures of main cannabinoids present in Cannabis sativa L. Abbreviation: Δ = heating; ox = oxidation; is =
isomerization.
which is a dyhydrostilbene unique to C. sativa, represents an
interesting compound [19]. If compared with cannflavin A,
which is the most potent cannflavin, canniprene has been
found to be superior at inhibiting 5-LO, but it is less effective
for mPGES-1 inhibition [19].
As regards the other compounds present in C. sativa,
terpenes are responsible for the characteristic scent of the
plant. Both mono- and sesquiterpenes have been detected
in roots and aerial parts of Cannabis and they are mainly
produced in secretory glandular hairs [2]. In the ambit
of monoterpenes, 𝛽-myrcene is known to possess anti-
inflammatory, analgesic, and anxiolytic properties [2]. As
for sesquiterpenes, 𝛽-caryophyllene has anti-inflammatory
and gastric cytoprotector activities; it is also able to bind to
the CB
2
receptors and, in this context, it is considered as a
phytocannabinoid [2].
Several interactions between Cannabis secondary metab-
olites have been described in the literature [2]. In addition
to the capacity of CBD to reduce Δ9-THC side effects,
terpenes are able to increase blood-brain barrier perme-
ability, thus affecting Δ9-THC pharmacokinetics; they can
also influence the affinity of Δ9-THC for CB
1
receptors and
interact with neurotransmitter receptors, thus contributing
to cannabinoid-mediated analgesic and psychotic effects [2].
Finally, also flavonoids may modulate the pharmacokinetics
of Δ9-THC, by means of the inhibition of hepatic P450
enzymes (3A11 and 3A4) [2].
1.1. Cannabidiol (CBD). Many studies have expanded the
concept that inflammation is a critical component of tumour
progression [20]. Indeed, several cancers originate from
infection, chronic irritation, and inflammation [20]. Tumour
microenvironment, which is largely regulated by inflamma-
tory cells, displays a key role in the neoplastic process, foster-
ing proliferation, survival, and migration [20]. In addition,
cancer cells have co-opted some of the signalling molecules
of the innate immune system for invasion, migration, and
metastasis [20].
By focusing the attention on hemp nonpsychoactive
cannabinoids, CBD has been demonstrated to be useful in
the treatment of different inflammatory ailments, including
bowel diseases (e.g., Crohn’s and ulcerative colitis), neuronal
diseases (e.g., Parkinson and Alzheimer), and a wide range
of inflammatory skin diseases (e.g., atopic dermatitis and
psoriasis) [21].
As regards cancer, CBD has exhibited antiproliferative
and proapoptotic activities, thus demonstrating modulating
the tumorigenesis in different types of cancer, including
breast, lung, colon, brain, and others [21].
In this context, this review is focused on the effects and
the molecular mechanisms of CBD and related compounds
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on inflammation and cancer processes, highlighting also
the role of other related nonpsychoactive cannabinoids and
noncannabinoids constituents of fibre-type hemp. Although
it has been reported that CBD is able to bind several protein
complexes, such as PPAR𝛾 and 5HT1, their role in CBD-
mediated anticancer activity is still poor documented. For
this reason, the attention is focusedmainly on the interaction
between CBD and three putative molecular targets such CB
2
,
GPR55, and TRPV1/2 protein receptors, where there is an
extensive literature and several molecular mechanisms have
been proposed.
2. The Role of the Endocannabinoid System in
Peripheral Inflammation
Endocannabinoids and their metabolic enzymes and recep-
tors have been identified in monocytes, macrophages,
basophils, lymphocytes, and dendritic cells. In these cells
their role is to modulate immune function in an autocrine
and paracrine way [22].
In human peripheral blood cells, CB
1
are expressed by B
cells, NK cells, neutrophils, CD8+ T cells, monocytes, and
CD4+ T cells, in a decreasing rank order, whereas CB
2
mRNA is expressed by human B cells, NK cells, monocytes,
neutrophils, and T cells, in a decreasing rank order [23].
CB
2
expression in human B cells increases after the
activation by anti-CD40 antibody. However, differentiation
of B cells is accompanied by decreased expression of CB
2
.
CB
2
levels in macrophages undergo changes correlated with
cell activation or with inflammation. Indeed, macrophages
express higher levels of CB
2
; so, the functions ofmacrophages
in these states of activation may be the most sensitive to the
actions of cannabinoids. These data suggest a physiological
role of the endocannabinoid system in the functions of
immune cells with respect to inflammation [24].
Both 2-arachidonylglycerol (2-AG) and anandamide
(AEA) play an immunomodulatory role through their activ-
ity on CB
2
. CB
2
activation typically inhibits the functions
of immune cells with intracellular signaling mechanisms,
including the inhibition of adenylate cyclase activity by Gi/o
proteins and activation of MAPKs. Indeed, CB
2
are able
to inhibit the production of proinflammatory cytokines,
like TNF-𝛼, IL-6, and IL-8 in human monocytes and
macrophages, and to reduce the release of TNF-𝛼, IL-2, and
IFN-𝛾 in activated human peripheral lymphocytes.
Moreover, a relationship between the endocannabinoid
system and toll-like receptors (TLR) has been reported,
with TLR activation enhancing the production of endo-
cannabinoids and cannabinoids suppressing TLR-induced
inflammatory response [25].
2.1. Nonpsychoactive Cannabinoids and Peripheral Inflamma-
tion. The study of the anti-inflammatory effects of cannabi-
noids fromC. sativaL. is of current interest [26, 27]. Although
Δ9-THC has been reported to possess anti-inflammatory in
a plethora of in vitro and in vivo models [28–38], a number
of reports have highlighted the role of nonpsychoactive
cannabinoids in inflammatory processes (Figure 2).
CBD anti-inflammatory effect may be mediated by can-
nabinoid receptors (CBr), adenosine A2A receptors, TRPV1
receptors, GPR55 receptors, and CB2/5HT(1A) heterodimer-
ization [27]. In vivo, CBD has been able to reduce inflamma-
tion in a murine model of colitis, even if Δ9-THC was more
effective [28]. In a carrageenan-induced inflammation model
in rats, CBD reduced PGE
2
, nitric oxide (NO), and malondi-
aldehyde production, together with COX activity [39]. CBDA
has been found to possess a dual inhibitory effect on COX,
through downregulation [40] and enzyme inhibition [35].
CBD has also completely inhibited the production of TNF-
𝛼 in LPS-stimulated RAW264.7 macrophages [41]. Moreover,
a reduction of IL-1𝛽 and TNF-𝛼 levels has been observed in
mitogen-activated human PBMC [42]. More recently, CBD
has been found to significantly reduce cytokines production
in an in vitro model of allergic contact dermatitis, using
HaCaT cells [43].
The ability to activate and desensitize TRPV4 channels
is linked to the reduction of NO production exerted by
CBG in LPS-stimulated macrophages [44]. Moreover, CBG
and CBGA resulted in inhibiting COX activity, even at high
micromolar concentrations [35].
CBC has reduced nitrites production, IL-10 and IFN-
𝛾 levels in murine macrophages, without influencing CBr
[25]. Moreover, CBC has decreased intestinal hypermotility
in mice, in a manner not dependent on CBr and TRPA1
receptors [45].
Concerning the effect of other C. sativa constituents,
cannflavins anti-inflammatory activity has been poorly inves-
tigated, but it seems to be related to the reduction of PGE
2
and
the inhibition of 5-lipoxygenase [18, 46].
As regards terpenes, myrcene and limonene are able
to reduce cytokines production and inhibit NF-𝜅B and
MAPK in LPS-stimulated murine macrophages [47]. 𝛽-
Caryophyllene reduced TNF-𝛼 and IL-1𝛽 production by
downregulating MAPK and reducing ERK phosphorylation
in LPS-stimulated PBMC [48].
As far as peripheral inflammation is concerned, C. sativa
has been used medicinally for centuries to treat a variety of
disorders, including those associatedwith the gastrointestinal
tract. Recent investigations have highlighted the involvement
of the endocannabinoid system in the physiology of the
gastrointestinal function and its possible deregulation in gas-
trointestinal pathology [49]. The precise mechanisms across
tissue departments that are under the regulatory control of
the endocannabinoid system have not been fully understood
[49].
Cannabinoids have been found to modulate intestinal
permeability in an in vitromodel. BothΔ9-THC and CBD are
able to restore the increased permeability induced by either
EDTA or endocannabinoids whether applied to the apical or
basolateralmembrane of Caco-2 cells [50].These data suggest
that endocannabinoids may play a role in the modulation
of gut permeability and that Cannabis-based medicines may
possess therapeutic benefit in a variety of gastrointestinal
diseases characterized by abnormal intestinal permeability,
such as inflammatory bowel disease (IBD) and shock [50].
These findings have been further confirmed in another
in vitro model of intestinal inflammation. In particular,
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Figure 2: General representation of the signaling pathways involved in CBD anti-inflammatory effects. Cannabinoids reduce peripheral
inflammation by acting at TRPV1, CB
2
, and GPR55 receptors; these interactions lead to downregulation of enzymes involved in the
production of prostaglandins, reactive oxygen species, and cytokines. MAPK inhibition and NF-kB downregulation, together with PPAR𝛾-
mediated reduction of lipid peroxidation, are also involved in the anti-inflammatory effects of cannabinoids in the CNS. Abbreviations: CBD,
cannabidiol; CNS, central nervous system, CB
2
, cannabinoid receptor 2; TRPV1, receptor potential channel subfamily V member 1; GPR55,
orphan G-protein coupled receptor 55; Akt, protein kinase B; ERK, extracellular signal-regulated kinases; NF-kB nuclear factor kappa-light-
chain-enhancer of activated B cells; iNOS, inducible nitric oxide synthase; COX2, cyclooxygenase 2; TNF-𝛼, tumor necrosis factor alpha;
PPAR𝛾, peroxisome proliferator-activated receptor gamma.
endocannabinoids caused further increases in Caco-2 cell
permeability in the presence of cytokines, whereas both
Δ9-THC and CBD restored increased permeability induced
by cytokines [51]. The effects of cytokines on increased
permeability were inhibited by a CB
1
receptor antagonist and
a 2-AG synthesis inhibitor and were enhanced by inhibitors
of the degradation of AEA or 2-AG, suggesting that local pro-
duction of endocannabinoids activating CB
1
may play a role
in the modulation of gut permeability during inflammation
[51].
CBD anti-inflammatory effects on the acutely inflamed
human colonhave also been investigated in combinationwith
palmitoylethanolamide (PEA) in cultured cell lines and this
effect was compared with experimentally inflamed explant
human colonic tissue [52]. In particular, Caco-2 cells and
human colonic explants collected from elective bowel cancer,
inflammatory bowel disease (IBD), or acute appendicitis
resections were used. CBD and PEA were able to prevent
cytokine production in human colonic explant tissue via
PPAR𝛼, CB
2
, and TRPV1, but not in Caco-2 cells [52]. These
effects extend into chronic inflammatory processes, such
as IBD, but also acute inflammatory conditions, such as
appendicitis. Since these two compounds are well tolerated
in humans with few side effects, their clinical use in treating
IDB can be very useful [52].
In another study, CBD has been demonstrated to improve
Clostridium difficile toxin A-induced damage in Caco-2
cells, by inhibiting the apoptotic process and restoring the
intestinal barrier integrity, through the involvement of CB
1
receptors [53]. Clostridium difficile infection is the leading
cause of hospital-acquired diarrhea and pseudomembra-
nous colitis. Clostridium difficile toxin A significantly affects
enterocytes permeability leading to apoptosis and colonic
mucosal damage. Given the absence of any significant toxic
effect in humans, CBD may ideally represent an effective
adjuvant treatment for Clostridium difficile-associated colitis
[53].
In addition to the protective role ofCannabis components
on the inflamed intestine, an additional positive aspect is their
potential role in preventing imbalances of gut microbiota.
This aspect not only is relevant for the treatment of several
gastrointestinal disorders, such as IBD and obesity, but also
has implications for the treatment of colorectal cancer (CRC).
The impact of the endocannabinoid system on gutmicrobiota
is a relatively new and emerging field wherein the interplay
between cannabinoids and metabolic syndrome has been the
focus so far. Recent data have suggested thatΔ9 -THCprevents
further exacerbation of the Firmicutes:Bacteroidetes ratio
typically found in obesity, resulting in weight-loss, indicating
that Cannabis may play a role in CRC prevention as well
[54]. Further studies are needed to determine whether CBD
has the same effect on gut microbiota with respect to the
balance of Firmicutes:Bacteroidetes to evaluate its application
in halting the progression of the obese microbiota profile
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present in CRC, with the hopes of delaying this disease onset
[54].
3. The Role of the Endocannabinoid
System in Neuroinflammation
CB
1
receptors are much more expressed in the brain if com-
pared to CB
2
[55]. However, CB
2
can be upregulated under
neuroinflammatory conditions and as a result of the invasion
of peripheral cells expressing CB
2
[56].
The neuroprotective effect of endocannabinoids involves
the suppression of proinflammatory cytokines and the
increase of anti-inflammatory cytokines production. This
altered expression is mainly mediated by the activation of the
MAPKs pathway and regulated primarily by MKP-1 [23].
A decrease of TNF-𝛼, IL-6, IL-1𝛽, and IL-12 levels in
rats brain has been observed after treatment with LPS in
several studies. Nevertheless, cannabinoids have been found
to increase the production of cytokines, including TNF-𝛼, IL-
6, IL-1𝛽, and IL-10, when administered alone [57].
Cytokines may regulate the normal activity of the endo-
cannabinoid system in different ways: for example, IL-4 and
IL-10 are able to stimulate FAAH activity, whereas IFN-𝛾 and
IL-12 decrease FAAH expression, resulting in an increase of
AEA levels [58, 59]. TNF-𝛼 and IL-6 are the major cytokines
which can regulate CBr activity. Indeed, these cytokines
have pro- and anti-inflammatory properties, depending on
a variety of factors. Recent studies have shown that TNF-
𝛼 provides a crucial signal for stem cells migration through
CB
1
/CB
2
signaling. The activation of TNF-𝛼 receptor then
leads to 2AG synthesis, which may act on CB
1
and CB
2
. This
activity leads to a promotion of stem cells proliferation and
migration that might have important implications for brain
self-repairing processes [60].
The cannabinoid system and cytokine network are direct-
ly related. CB
1
and CB
2
expression is significantly induced
by the presence of TNF-𝛼. This occurs, at least in part,
through the activation of NF-𝜅B, which could be induced
by stimulation of TNF receptor. Upon activation, NF-𝜅B
translocates into the nucleus, where it bindsDNAand triggers
the transcription of target genes, some of which encode
inflammatory proteins and may include the CBr genes [61].
3.1. Nonpsychoactive Cannabinoids and Neuroinflammation.
Evidences suggest that controlled neuroinflammation is cru-
cial for tissue repair within the brain [62, 63]. However,
prolonged exposure to inflammatory conditions in the brain
has been linked with the development of neurodegenerative
diseases, such as the Alzheimer’s and Parkinson’s diseases,
and multiple sclerosis [64]. In Alzheimer’s disease, misfolded
and aggregated proteins are recognized bymicroglia and acti-
vate an innate immune response characterized by the release
of inflammatory mediators, contributing to the disease pro-
gression and severity [65]. The role of neuroinflammation
in the pathogenesis of Parkinson’s diseases is supported by
several experimental evidences, even if it remains unclear
whether the inflammatory processes are involved in the
initiation of the disease or are secondary consequences
of the brain injury [66, 67]. Regarding multiple sclerosis,
inflammation appears to bemediated by T-helper 1 cells, with
enhanced presence of Th1/Th17 cells being found in central
nervous system (CNS) tissue, cerebrospinal fluid (CSF), and
blood of patients [68, 69].
C. sativa and its constituents have been reported to be
promising candidates for the management of several neu-
roinflammatory conditions (Figure 2) [70]. CBD, similarly to
Δ9-THC, has been able to reduce neurotoxicity in SH-SY5Y
neuronal cells exposed to LPS-conditioned BV2 microglial
cells medium, by modulating BV2 morphological plasticity
and cytokines signaling through the activation of GPR18
receptors [71].
In an in vitro model of neuroinflammation using LPS-
stimulated rat microglia, CBD has suppressed TNF-𝛼, IL-
1𝛽, and IL-6 release, by reducing NF-𝜅B phosphorylation,
together with COX and iNOS activation, in a CB
2
dependent
manner [72, 73]. Interestingly, CBD has caused a downregu-
lation of Akt and ERK pathways in human glioma cells [74].
The inhibition of ATP-induced intracellular calcium increase,
together with the inhibition of NO production, has been sug-
gested as a mechanism by which CBD can reduce microglia
activation [75]. In cultured rat primary astrocytes, CBD has
reduced the A𝛽-induced release of NO, IL-1𝛽, and TNF-𝛼, by
activating PPAR𝛾 and inhibitingNF-𝜅Bnuclear translocation
[76]. In another work, CBD has also inhibited the neurotoxic
effects of protease-resistant prion protein (PrPres) and it
has affected PrPres-induced microglial cell migration in a
concentration-dependent manner; so, it may protect neurons
against the multiple molecular and cellular factors involved
in the different steps of the neurodegenerative process, which
takes place during prion infection [77]. More recently, the
neuroprotection of fibre-type hemp extracts and CBD was
assessed in human neuroblastoma SH-SY5Y and microglial
BV-2 cell lines in the presence of rotenone as the toxic agent,
also in serum-free conditions [78].The decarboxylated hemp
extract has shown a mild neuroprotective activity on BV-2
cells treatedwith rotenone, higher than that of pureCBD [78].
As regards serum-free experiments, the nondecarboxylated
hemp extract was the most effective neuroprotective agent
toward SH-SY5Y cells, while BV-2 cells were better protected
from the toxic insult by the decarboxylated extract and CBD
[78].
Concerning other cannabinoids, the anti-inflammatory
properties of CBG have been described in an in vitromodel of
neuroinflammation, using NSC motor neurons conditioned
with the medium of LPS-stimulated murine macrophages.
CBG treatment in macrophages has prevented neuronal
cytotoxicity by reducing inflammation, (i.e., IL-1𝛽, TNF-𝛼,
and IFN-𝛾 production, together with PPAR𝜇 protein levels)
and oxidative stress, reducing nitrotyrosine, SOD1, and iNOS
protein levels and restoring Nrf-2 levels [79].
As regards other C. sativa components, 𝛽-caryophyllene
is able to reduce the production of IL-1𝛽, TNF-𝛼, IL-6, and
ROS, through the inhibition of NF-kB nuclear translocation
in murine microglial cells, after hypoxic exposure [80].
In the ambit of CNS pathology and, in particular, regard-
ing Alzheimer’s disease, studies in rodents have demon-
strated the ability of CBD to reduce reactive gliosis and
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neuroinflammatory response as well as to promote neuro-
genesis [81]. Moreover, in an in vitro model using SH-SY5Y
human neuroblastoma cells, CBD has been able to induce
ubiquitination of APP protein, reducing 𝛽-amyloid peptide
production and neuronal apoptosis through activation of
PPAR𝛾 [82]. These results are consistent with those obtained
by Hughes and coworkers, who have observed a PPAR𝛾
mediated neuroprotective effect of CBD in the hippocampus
of C57Bl/6 mice [83].
4. Inflammation and Cancer
Cancer is the second leading cause of death worldwide,
and it accounts for about 8.8 million deaths in 2015 (GHO
2018 data); nearly 1 of 6 deaths is due to cancer. Cancer
is a multistep disease characterized by a formation of a
preneoplastic lesion (initiation processes) which, by time,
progresses into malignant tumor. Generally, cell transforma-
tion is a combination of intrinsic genetic factors and external
exposure to physical, chemical, and biological carcinogens.
However, it must be underlined that ageing and life style
are others fundamental factors for the development of the
disease. Indeed, the incidence of cancer rises dramatically
with age, probably due to the decreased efficacy of cellular
repair mechanisms, while tobacco, alcohol, unhealthy diet,
and physical inactivity are the major global cancer risks. A
number of evidences pointed out that chronic inflammation,
independently of the triggering agent, could be responsible
of almost 20% of human cancers [84]. As described above,
inflammation per se is not dangerous, since it protects the
body by increasing host defense and it is self-limiting. How-
ever, persistent and deregulated inflammation is associated
with an increased risk of malignant diseases [85]. Cells and
mediators of the innate immune system have been detected
in many cancers, even when inflammation is not implicated
in tumor development [85, 86]. This finding suggests that
inflammatory conditions and carcinogenesis might share
common pathways, such as proliferation, increased cell sur-
vival, and migration, where cytokines and growth factors
play a pivotal and fundamental role. Therefore, not only can
inflammation cause cancer, but also cancer causes inflam-
mation [87]. Thus, in the tumor microenvironment, inflam-
matory mediators regulate a number of proinflammatory
responses, acting in an autocrine and/or paracrine manner,
leading to either an antiproliferative response or an increase
of cancer promotion through the inhibition of protective
immune response [88]. In this context, it has been shown that
the activation of the proinflammatory NF-kB pathway has a
tumor prosurvival effect, giving chemotherapy resistance to
cancer cells in anAkt-independent pathway, but involving the
epidermal growth factor (EGF) activating signaling [89].This
interesting link between inflammation and growth factors,
such as EGF/EGFR, configures an intriguing perspective in
the study of the possible correlation between inflammatory
processes and aberrant cell growth. Studies carried out on
liver cancer have shown that chronic tissue damage and
inflammation in liver result in a sustained overexpression
and overstimulation of the EGFR pathway and that the
deregulated EGFR signaling has been reported to play an
important role in the development of liver cancer [89].
Proinflammatory stimuli activated by EGFR promote the
release of EGFR ligands, such as heparin-binding-EGF (HB-
EGF), from liver cancer cells and endothelial cells, which
stimulate the proliferation of initiated hepatocytes [89], and
further potentiate their aggressive behavior [90]. Moreover,
the finding that CBD suppresses the activation of EGF/EGFR
signaling transduction pathway and its downstream targets
Akt, ERK, and NF-kB suggests that the effect of C. sativa
extract might play an important in the modulation on the
intricate relationship between growth factors, inflammation,
and cell growth [90]. Indeed, the ability to inhibit proin-
flammatory pathways, as described in the previous chapter,
strongly indicates that cannabinoids are antiproliferative
compounds by possibly interfering with NF-kB/EGF/EGFR
pathway.This hypothesis has been further supported by Elbaz
et al. [91], who have demonstrated that CBD, acting on its
receptors, changes cytokine secretion, such as CCL3, GM-
CSF, and MIP-2 proteins, from 4T1.2 tumor cells compared
to vehicle-treated cells, thus decreasing the recruitment of
macrophages to the tumor microenvironment and, therefore,
suppressing both angiogenesis and the invasive potential of
cancer cells. In addition, the presence of GPR55 receptor,
which is able to bind CBD, on NK cells, represents a possible
novel modulatory activity of NK cell responsiveness [92].
Noteworthy, the noncanonical cannabinoid receptor G cou-
pled receptor GPR55-mediated NK cell stimulation and/or
inhibition is of particular importance in tumor immune-
surveillance, since these cells play a pivotal role in the
recognition and elimination of malignant cells.
5. The Role of the Endocannabinoid
System in Cancer
The role of the endocannabinoid system in cancer biology is
a controversial matter. Indeed, if on one hand an increase,
although with a different pattern and extent, of endocannabi-
noid receptors CB
1
and CB
2
in various types of cancers
has been observed, on the other hand the endocannabinoid
system seems to play a tumor suppressing role on colon
carcinoma in a genetic modified mouse model, carrying
a knockdown of CB
1
gene [93]. However, the majority of
researches have reported an increase of CB
1
and CB
2
in
different types of cancer. In particular, CB
1
receptor has been
found to be upregulated in cellular hepatocarcinoma [94]
and in Hodgkin lymphoma cells [95], and its expression
correlates with the severity of the disease in human epithelial
ovarian cancer [96], whereas CB
2
has been found to be
overexpressed in human breast adenocarcinomas associated
with HER2+ [97] and in glioma [98]. Moreover, CB
1
and CB
2
expression has been proposed to be a factor of bad prognosis
following surgery in stage IV of colorectal cancer [99].
All these findings support the hypothesis that cannabinoids
might interfere with cancer biology, acting on CB
1
and CB
2
receptors in a wide range of cancer types, in particular forΔ9-
tetrahydrocannabivarin (Δ9-THCV), which is a homologue
of Δ9-THC with a propyl side chain instead of a pentyl
group. However, since nonpsychoactive cannabinoids, such
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Figure 3: General representation of the signaling pathways involved in CBD anticancer mediated effects. Cannabinoid-induced apoptosis
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as CBD, do not bind with high affinity to both CB
1
and
CB
2
, alternative pathways should be considered in order
to analyze the molecular mechanisms of CBD anticancer
activity (Figure 3).
5.1. Nonpsychoactive Cannabinoids and Cancer. In cancer
treatment, cannabinoids, such as dronabinol (synthetic Δ9-
THC) and nabilone (a synthetic cannabinoid similar to Δ9-
THC), are mainly used in association with chemotherapy in
order to decrease its side effects such as pain, weight loss,
nausea, and vomiting, although their use is still limited due
to their psychoactive side effects [100]. However, incoming
evidences have suggested that their activity could not be
ascribed solely to these “palliative” effects, but rather the
compounds could possess some interesting properties in
terms of inhibition of tumor cell proliferation.
The first evidence of the ability of cannabinoids, and in
particular Δ9- and Δ8-THC (Figure 1), to reduce the growth
of lung adenocarcinoma both in vitro and in vivo has been
reported by Munson et al. in 1975 [101]. As mentioned above,
in recent years a number of researches have been made
to evaluate the antiproliferative and proapoptotic effects
of cannabinoids in both in vitro and in vivo models and
in different cancer types, such as glioma, breast, pancreas,
prostate, colorectal and lung carcinoma, and lymphoma [102–
109]. These results prompted up the research of the possible
molecular mechanism involved in the effects mediated by
cannabinoids, together with the discovery of new activities
elicited by these compounds, such as the interference with
angiogenesis, cancer cell migration, and invasion [110]. All
these findings strongly reinforce the idea that these com-
pounds are able to control the cell survival/death fate and,
therefore, they could be good candidates in cancer therapies.
5.2. Nonpsychoactive Cannabinoids and GPR55. GPR55 is
a, so-called, orphan receptor protein, constituted by 319
amino acids, and it is present in the chromosome 2q37 [111].
GPR55 has been identified for the first time in 1999, and it
belongs to the 𝛿 group of rhodopsin-like G protein coupled
receptors (GPCRs) [112]. GPR55 possesses different biological
functions based upon its localization: it controls the motility
of the gastrointestinal tract, angiogenesis, and neuropathic
pain; it modulates the inflammatory processes and it is
involved in intracellular signaling involving the upstream
signaling of RhoA, ROCK, ERK, and p38 mitogen activated
protein kinase pathways, and Ca2+ release, which in turn
modulate the downstream, cell motility and stiffness and the
transcription factors nuclear factor activated T cell (NFAT),
nuclear-factor-kB (NF-kB), cAMP response elements bind-
ing protein (CREB), and the activating transcription factor-
2 (ATF2) [113–115]. The modulation of these important
biological determinants indicates that GPR55 is a possi-
ble pharmacological target in a number of diseases where
these pathways are deregulated, such as cancer. Increased
expression of GPR55 and severity and malignancy of the
disease has been reported in different cancer types, such as
the human pancreatic ductal adenocarcinoma, the squamous
cell carcinomas human astrocytoma, the melanoma, the B
lymphoblastoma [116–118], and the hepatocellular carcinoma
as well [94]. Although the pharmacology of GPR55 remains
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controversial, a number of evidences have suggested that
it is a non-CB
1
/CB
2
receptor able to bind nonpsychoactive
cannabinoids and CBD in particular is its putative ligand,
acting as an antagonist [119, 120]. In this view, Shrivastava
et al. [121] have demonstrated that CBD is able to kill breast
cancer cells by inducing ER stress, enhancing ROS genera-
tion and inhibiting mTOR signaling. In addition, CBD has
been found to regulate the balance between autophagy and
mitochondria-mediated apoptosis. This latter effect could be
mediated by the antagonistic effect of CBD to GPR55, since
its inhibition with anandamide allows the recruitment of the
death receptor Fas into cell membrane through the activation
of protein G𝛼12 and Jun N-terminal kinase [113]. Moreover,
Solinas et al. [74] have shown the antiproliferative and anti-
invasive effects of CBD in U87-MG cells in a CB
1
/
2
indepen-
dent manner, and these effects have been extended to T98G
glioma cells, a Δ9-THC-resistant lineage, thus suggesting a
possible alternative pathway from that involving CB
1
/CB
2
receptors. CBD effects aremediated by a significant downreg-
ulation of ERK and PI3K/Akt kinases, which are fundamental
for cell survival and proliferation (Figure 3). The finding that
stable overexpression of this GPR55 in HEK293 cells led
to increased levels of phosphorylated extracellular signal-
regulated kinase (ERK) [117] involved in cell proliferation
strongly indicates that GPR55 is a target for CBD-mediated
anticancer activity. Moreover, the fact that CBD downreg-
ulates the expression of angiogenic related proteins both in
vitro and in vivo, such as matrix metallopeptidase 9 (MMP9),
tissue inhibitor of metalloproteinases 1 (TIMP1), serpinE1-
plasminogen activator inhibitor type-1 (PAI-1), CXCL16, ET-
1, PDGF-AA, and IL-8 [74], reinforces the hypothesis that
CBD might exert its antiangiogenic activity through the
interaction with GPR55. Indeed, a clear relationship between
GPR55 and angiogenesis has been reported by Zhang et al.
[122], where the endothelial vascular cells regulate GPR55-
mediated angiogenesis through the autocrine release of
LPI; once GPR55 was downregulated in primary human
microvascular endothelial cells, a decrease in angiogenesis
was observed. Even if all these data clearly indicate that
the antagonism of CBD on GPR55 activity inhibits cancer
cell proliferation and angiogenesis and increases apoptosis,
further studies are necessary, in order to better understand
and to complete the portrait of the relation between CBD,
GPR55, and cancer biology both in in vitro and in vivo
models. Moreover, other protein receptors may be able to
bind CBD, and in turn they can be of importance in the
modulation of cancer growth.
5.3. Cannabinoids and TRPVs. Beside the discussed GPR55
receptors for nonpsychoactive cannabinoids, another non-
CB
1
/CB
2
receptor system, i.e., the transient receptor protein
of vanilloid types 1 and 2 (TRPV1, TRPV2), has been pro-
posed to bind either endocannabinoid or phytocannabinoids.
The TRP receptors control mainly body temperature percep-
tion, thermal pain, and noxious stimuli and they are involved
in several biological functions, such as cell proliferation [123].
In particular, the TRPV vanilloid channels belong to a
superfamily of channels called “Transient Receptor Potential”
(TRP), which promote calcium entry into the cells. The
most extensively studied receptor in the ambit of the TRPV
family is represented by TRPV1. TRPV1 and TRPV2 are
ubiquitously expressed throughout the body, with a particular
abundance in the central nervous system (CNS), and they
differ both in the activities that they mediate and in their
pharmacological profiles [124]. TRPV1 is activated by heat
and, once activated, it allows the entrance of calcium and
magnesium into the cells. Upon activation, the channel
undergoes a rapid desensitization in a Ca-dependentmanner.
TRPV1 is modulated by a number of bioactive com-
pounds, such as capsaicin, piperine, camphor, CBD, and the
endocannabinoid anandamide, which activate the channel.
TRPV2 is not modulated by pungent-tasting compounds,
such as capsaicin or piperine, but it shares with TRPV1
the activation elicited by CBD, related cannabinoids, and
probenecid. It differs also from TRPV1 for its role in various
osmo- or mechanosensory activities rather than noxious heat
stimuli [125]. So, both TRPV1 and TRPV2 receptors are acti-
vated by CBD [126, 127], allowing an increase of intracellular
Ca2+ [128].The activation and the subsequent desensitization
of these receptor proteins, which are involved in transducing
acute inflammatory and chronic pain (especially TRPV1),
might be responsible for the antihyperalgesic actions of CBD
[127]. Interestingly, the results found on prostate and skin
cancers cells have shown that both TRPV1 and TRPV2 are
involved in cancer progression, thanks to their ability to
interact with G-proteins and, therefore, to interfere with
intracellular signaling and to modulate intracellular Ca2+
[129, 130]. Protein receptors are differently up- and downreg-
ulated in cancer tissues, thus indicating a possible different
role in cancer progression. In particular, TRPV1 is upregu-
lated in glioma, prostate, and pancreas cancers, whereas it is
downregulated in hepatocellular carcinoma (HCC), bladder,
and skin cancer [123]. TRPV2 is upregulated in bladder,
prostate, and HCC, while it is downregulated in glioma can-
cer cells [123]. In this context, it has been demonstrated that
the concomitant overexpression of TRPV2 and insulin-like
growth factor 1 (IGF-1) suggests that TRPV2 might control
the urothelial cancer cell growth and progression through
the modulation of IGF-1 pathway [131]. In U87MG glioblas-
toma/astrocytoma cell line, TRPV2 decreases cellmalignancy
and cell survival in an ERK dependent manner [123]. In
addition, TRPV1 has been found to be colocalized with the
proapoptotic protein Fas/CD95, and, when stimulated with
the agonist capsaicin, it causes a cell cycle arrest in G0/G1
in RT4 and apoptosis in urothelial cancer cells [132]. So, the
interaction with an agonist on TRPV1 or TRPV2 receptors
could originate different biological responses, depending on
the distribution of TRPV, together with the fine interactions
with other molecular complexes. In this view, CBD has
been found to inhibit the multidrug resistance (MDR), by
interacting with TRPV1 and CB
2
at the same time (Figure 3).
Indeed, in the MDR CEM/VLB100 cell model, Arnold et
al. have reported that the treatment with CBD caused a
downregulation of P-glycoprotein (P-gp) expression and an
increase of the cytotoxic effects of vinblastine, whose P-gp is
the substrate [133] However, this effect was mediated both by
the cooperation of CBD with TRPV1 and by CB
2
receptors,
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indicating once more the intricate complexity of interaction
between biological pathways. Moreover, the ability of CBD
to increase the cytotoxic activity of anticancer agents, such
as temozolomide, doxorubicin, and carmustine in U87MG
cancer cells, allowed Nabissi et al. [134] to discover that
this effect was due to the interaction of CBD with TRPV2
receptor, which resulted in an increase of drug uptake. This
interesting finding could be of relevance also in the manage-
ment of glioma cancer stem cells (GSCs). Indeed, it has been
reported that TRPV2 activation led to a GSCs differentiation
and, therefore, to an inhibition of their proliferation [135].
This effect could be due, at least in part, to the ability of
CBD to upregulate the prodifferentiation factor ID2 and to
downregulate the metastatic factor ID1 [136], since both these
proteins play an important role in spreading neuroblastoma
cells [137]. Taking into account the fact that GSCs are the
major factor responsible for glioma recurrence, the use of
CBD could also be a valuable tool against the proliferation
of the GSCs subpopulations present in glioma/glioblastoma
cancers.
6. Hemp Extracts and CBD between
Present and Future
This review is mainly focused on the role of CBD and
related nonpsychoactive compounds in themodulation of the
inflammatory processes linked to the degenerative diseases
and, in particular, to cancer. From a pharmaceutical point
of view, CBD represents at the moment the most promising
compound present in C. sativa. Although this component is
well-knownmainly for its antioxidant and anti-inflammatory
activities, a number of researches pointed out its ability to
interfere with cell proliferation apoptosis and cancer growth.
If we consider also that cancer biology and inflammation
share several common pathways in some stages of their
biological processes, CBDmight be a potential important tool
in the control of cancer spread and growth.
It is important however to consider also other issues
regarding cannabinoids and their use, comprising the poor
availability of the plant material, the uncertainties on the
quality of the products, and the safety of CBD. For these
reasons, CBD is under scrutiny at many levels, ranging from
national health organizations to FDA and WHO. Up to now,
many clinical trials have been performed on Sativex, which
is a combination of Δ9-THC and CBD, or on Epidiolex,
which is currently in phase three, with encouraging results
against a severe form of epilepsy in children.
However, one of the main points under debate is whether
cannabinoids and CBD, in particular, are safe for consumers
at the doses found to be active in the experimental conditions,
by taking into account the fact that there is only limited
knowledge about the long-term effects of chronic use and
drug-drug interactions between CBD and other medications,
although human studies have indicated that CBD is very
well tolerated even at high doses. Another important issue
is whether or not Cannabis extracts or CBD are simply a
food supplement, a pharmaceutical product, or other. If on
one hand this perplexity is justified by the need for a reliable
evaluation of the balance between efficacy and side effects, on
the other hand it must be recognized that, in some cases, an
unconscious prejudice seems to hover on C. sativa, mainly
because of its history of drug of abuse.
We believe that although an important number of studies
regarding the therapeutic effects of CBD have been per-
formed in the last decade, there is no solid clinical evidence
yet to support that cannabinoids can effectively and safely
treat cancer in humans. However, by taking into account
the fact that hemp extracts with low Δ9-THC concentration
but rich in nonpsychoactive compounds are still poorly
studied from a pharmacological and molecular point of
view, we think that they could be a precious resource for
future treatment of both acute and chronic diseases. In
addition, by considering the availability of specific cultivars
containing different amounts of active compounds, such as
flavonoids and terpenes, it might be possible to select the
appropriate variety enriched of a specific class of compounds
to be used for a specific disease. Moreover, if we consider
that the treatment of most degenerative diseases is still far
from achieving full success, the research on hemp and CBD
extracts is strongly encouraged in order to have enough data
for a rational clinical application.
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